WHAT IS CLAIMED IS:

1. A compound represented by Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein

HET is one of the following heterocycles:



R^1 is

(a) H;

(b) C_1-C_6-alkyl, C_2-C_4-alkenyl, C_2-C_4-alkynyl,C_3-C_6-cycloalkyl, or C_1-C_4-alkyl-[C_3-C_6-cycloalkyl], any of which is optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-C_4)alkyl, $S(O)_{0-2}$-(C_1-C_4)alkyl, O-$CONR^aR^b$, NR^aR^b, $N(R^a)CONR^aR^b$, COO-(C_1-C_4)alkyl, COOH, CN, $CONR^aR^b$, $SO_2NR^aR^b$, $N(R^a)SO_2NR^aR^b$, -C(=NH)NH_2, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;

(c) -O-C_1-C_6-alkyl, -O-C_3-C_6-cycloalkyl, -S-C_1-C_6-alkyl or -S-C_3-C_6-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-C_4)alkyl, $S(O)_{0-2}$-(C_1-C_4)alkyl, O-$CONR^aR^b$, NR^aR^b, $N(R^a)CONR^aR^b$, COO-(C_1-C_4)alkyl, COOH, CN, $CONR^aR^b$, $SO_2NR^aR^b$, $N(R^a)SO_2NR^aR^b$, -C(=NH)NH_2, tetrazolyl, triazolyl, imidazolyl, oxazolyl,

oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;

(d) -C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl, or -O-C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl;

(e) -OH;

(f) -O-aryl, or –O-C_1-C_4-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO_2, iv) –C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C_{0-4}alkyl-CO-OR^a, viii) -(C_{0-4}alkyl)-NH-CO-OR^a, ix) -(C_{0-4}alkyl)-CO-N(R^a)(R^b), x) -$S(O)_{0-2}R^a$, xi) -$SO_2N(R^a)(R^b)$, xii) -$NR^aSO_2R^a$, xiii) -C_{1-10}alkyl, and xiv) -C_{1-10}alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -$S(O)_{1-2}$-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C- ;

(g) -OCON(R^a)(R^b), or -$OSO_2N(R^a)$(R^b);

(h) -SH, or -SCON(R^a)(R^b);

(i) NO_2;

(j) NR^aR^b, -N(COR^a)R^b, -N(SO_2R^a)R^b, -N(R^a)$SO_2N(R^a)_2$, -N(OR^a)$CONR^aR^b$, -N(R^a)SO_2R^a or -N(R^a)$CON(R^a)_2$;

(k) -CH(OR^a)R^a, -C(OR^b)CF_3, -CH(NHR^b)R^a, -C(=O)R^a, C(=O)CF_3, -$SOCH_3$, -SO_2CH_3, $COOR^a$, CN, $CONR^aR^b$, -$COCONR^aR^b$, -$SO_2NR^aR^b$, -CH_2O-$SO_2NR^aR^b$, $SO_2N(R^a)OR^a$, -C(=NH)NH_2, -CR^a=N-OR^a, CH=$CHCONR^aR^b$;

(l) -$CONR^a(CH_2)_{0-2}C(R^a)(R^b)(CH_2)_{0-2}CONR^aR^b$;

(m) tetrazolyl, tetrazolinonyl, triazolyl, triazolinonyl, imidazolyl, imidozolonyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrazolonyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, or phenyl, any of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO_2, iv) -C(=O)R^a, v) C_1-C_6-alkyl , vi) -O-R^a, vii) -NR^aR^b , viii) - C_0-C_4-alkyl - CO-O R^a, ix) -(C_0-C_4-alkyl)-NH-CO-OR^a, x) -(C_0-C_4-alkyl)-CO-NR^a R^b, xi) –$S(O)_{0-2}R^a$, xii) -$SO_2NR^aR^b$, xiii) -$NHSO_2R^a$, xiv) –C_1-C_4-perfluoroalkyl, and xv) –O-C_1-C_4-perfluoroalkyl;

(n) -C(R^a)=C(R^b)-$COOR^a$, or -C(R^a)=C(R^b)-$CONR^aR^b$;

(o)



(p) piperidin-1-yl, morpholin-4-yl, pyrrolidin-1-yl, piperazin-1-yl or 4-susbstituted piperazin-1-yl, any of which is optionally substituted with 1-3 substituents selected from i) -CN, ii) -C(=O)(R^a), iii) C_1-C_6-alkyl , iv) -OR^a, v) -NR^aR^b, vi) -C_0-C_4-alkyl-CO-OR^a, vii) -(C_0-C_4-alkyl)-NH-CO-OR^a, viii) -(C_0-C_4-alkyl)-CON(R^a)(R^b), ix) -SR^a, x) -$S(O)_{0-2}R^a$, xi) -$SO_2N(R^a)(R^b)$, xii) -$NR^aSO_2R^a$ xiii) -C_1-C_4-perfluoroalkyl and xiv) -O-C_1-C_4-perfluoroalkyl;

R^a is

(a) H;

(b) C_1-C_4-alkyl, optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-C_4)alkyl, $S(O)_{0-2}$-(C_1-C_4)alkyl, -$OCONH_2$, -OCONH(C_1-C_4alkyl), -OCON(C_1-C_4alkyl)(C_1-C_4alkyl), -OCONHC_1-C_4alkyl-aryl), -OCON(C_1-C_4alkyl)(C_1-C_4alkyl-aryl), NH_2, NH(C_1-C_4alkyl), N(C_1-C_4alkyl)(C_1-C_4alkyl), NH(C_1-C_4alkyl-aryl), N(C_1-C_4alkyl)(C_1-C_4alkyl-aryl), $NHCONH_2$, NHCONH(C_1-C_4alkyl), NHCONH(C_1-C_4alkyl-aryl), -NHCON(C_1-C_4alkyl)(C_1-C_4alkyl), NHCON(C_1-C_4alkyl)(C_1-C_4alkyl-aryl), N(C_1-C_4alkyl)CON(C_1-C_4alkyl)(C_1-C_4alkyl), N(C_1-C_4alkyl)CON(C_1-C_4alkyl)(C_1-C_4alkyl-aryl), COO-(C_1-C_4-alkyl), COOH, CN, $CONH_2$, CONH(C_1-C_4alkyl), CON(C_1-C_4alkyl)(C_1-C_4alkyl), SO_2NH_2, SO_2NH(C_1-C_4alkyl), SO_2NH(C_1-C_4alkyl-aryl), SO_2N(C_1-C_4alkyl)(C_1-C_4alkyl), $NHSO_2NH_2$, -C(=NH)NH_2, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;

(c) C_0-C_4-alkyl-(C_1-C_4)-perfluoroalkyl; or

(d) C_1-C_4-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO_2, iv) –C(=O)(C_1-C_4-alkyl), v) -O(C_1-C_4-alkyl), vi) -N(C_1-C_4-alkyl)(C_1-C_4-alkyl), vii) -C_{1-10}alkyl, and viii) -C_{1-10}alkyl,wherein one or more of the alkyl carbons can be replaced by a - O-, -$S(O)_{1-2}$-, -O-C(O)-, -C(O)-O-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-;

R^b is

(a) H; or

(b) C_1-C_6-alkyl, optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-C_4)alkyl, $S(O)_{0-2}$-(C_1-C_4)alkyl, -$OCONH_2$, -OCONH(C_1-C_4alkyl), NH_2, NH(C_1-C_4alkyl), N(C_1-C_4alkyl)(C_1-C_4alkyl), $NHCONH_2$, NHCONH(C_1-C_4alkyl), -NHCON(C_1-C_4alkyl)(C_1-C_4alkyl), COO-(C_1-C_4-alkyl), COOH, CN, and $CONH_2$;

R^2 is:

(a) H;

(b) -C_1-C_4-alkyl, -C_3-C_6-cycloalkyl or -C_1-C_4-alkyl-(C_3-C_6)-cycloalkyl, optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-C_4)alkyl, $S(O)_{0-2}$-(C_1-C_4)alkyl, O-$CONR^aR^b$, NR^aR^b, $N(R^a)CONR^aR^b$, COO-(C_1-C_4)alkyl, COOH, CN, $CONR^aR^b$, $SO_2NR^aR^b$, $N(R^a)SO_2NR^aR^b$, -$C(=NH)NH_2$, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl and piperazinyl;

(c) -C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl;

(d) aryl or -(C_1-C_4-alkyl)-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO_2, iv) –C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C_{0-4}alkyl-CO-OR^a, viii) -(C_{0-4}alkyl)-NH-CO-OR^a, ix) -(C_{0-4}alkyl)-CO-$N(R^a)(R^b)$, x) -$S(O)_{0-2}R^a$, xi) -$SO_2N(R^a)(R^b)$, xii) -$NR^aSO_2R^a$, xiii) -C_{1-10}alkyl, and xiv) -C_{1-10}alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, - O-, -$S(O)_{1-2}$-, -O-C(O)-, -C(O)-O-, -C(O)-$N(R^a)$-, -$N(R^a)$-C(O)-, -$N(R^a)$-C(O)-$N(R^a)$-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-;

(e) -C(=O)(R^a), -$CONR^aR^b$, COO-(C_1-C_4)alkyl, - SO_2R^a, -$SO_2N(R^a)(R^b)$;

R^3 is

(a) H;

(b) -C_1-C_4-alkyl, -C_3-C_6-cycloalkyl or -C_1-C_4-alkyl-(C_3-C_6)-cycloalkyl, optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-C_4)alkyl, $S(O)_{0-2}$-(C_1-C_4)alkyl, O-$CONR^aR^b$, NR^aR^b, $N(R^aR^b)CONR^aR^b$, COO-(C_1-C_4)alkyl, COOH, CN, $CONR^aR^b$, $SO_2NR^aR^b$, $N(R^aR^b)SO_2NR^aR^b$, -$C(=NH)NH_2$, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;

(c) -C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl;

(d) aryl or -(C_1-C_4-alkyl)-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO_2, iv) –C(=O)(R^a), v)

$-OR^a$, vi) $-NR^aR^b$, vii) $-C_{0-4}$alkyl-CO-OR^a, viii) $-(C_{0-4}$alkyl)-NH-CO-OR^a, ix) $-(C_{0-4}$alkyl)-CO-$N(R^a)(R^b)$, x) $-S(O)_{0-2}R^a$, xi) $-SO_2N(R^a)(R^b)$, xii) $-NR^aSO_2R^a$, xiii) $-C_{1-10}$alkyl, and xiv) $-C_{1-10}$alkyl, wherein one or more of the alkyl carbons can be replaced by a $-NR^a-$, -O-, $-S(O)_{1-2}-$, -O-C(O)-, -C(O)-O-, $-C(O)-N(R^a)-$, $-N(R^a)-C(O)-$, $-N(R^a)-C(O)-N(R^a)-$, -C(O)-, -CH(OH)-, -C=C-, or -C≡C- ;

(e) $-O-C_1-C_4$-alkyl, $-O-C_0-C_4$-alkyl-C_1-C_4-perfluoroalkyl, -O-aryl or $-O(C_1-C_4$-alkyl)-aryl;

(f) $-C(=O)(R^a)$, $-SO_2R^a$, $-SO_2N(R^a)(R^b)$, CN, NR^aR^b, NO_2, F, Cl, Br, I, OH, $OCONR^aR^b$, $O(C_1-C_4$-alkyl)$CONR^aR^b$,$-OSO_2NR^aR^b$, $COOR^a$, or $CONR^aR^b$;

R^4 and R^5 each independently is:

(a) H;

(b) $-C_1-C_6$-alkyl, $-C_2-C_6$-alkenyl, $-C_2-C_6$-alkynyl or $-C_3-C_6$-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF_3, $-O-(C_1-C_4)$alkyl, CN, $-N(R^a)(R^b)$, $-N(R^a)CO-(C_1-C_4)$alkyl, $COOR^b$, $CON(R^a)(R^b)$ or phenyl;

(c)$-O-C_0-C_6$-alkyl, -O-aryl, or $-O-C_1-C_4$-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) $-NO_2$, iv) $-C(=O)(R^a)$, v) $-OR^a$, vi) $-NR^aR^b$, vii) $-C_{0-4}$alkyl-CO-OR^a, viii) $-(C_{0-4}$alkyl)-NH-CO-OR^a, ix) $-(C_{0-4}$alkyl)-CO-$N(R^a)(R^b)$, x) $-S(O)_{0-2}R^a$, xi) $-SO_2N(R^a)(R^b)$, xii) $-NR^aSO_2R^a$, xiii) $-C_{1-10}$alkyl, and xiv) $-C_{1-10}$alkyl,wherein one or more of the alkyl carbons can be replaced by a $-NR^a-$, -O-, $-S(O)_{1-2}-$, -O-C(O)-, -C(O)-O-, $-C(O)-N(R^a)-$, $-N(R^a)-C(O)-$, $-N(R^a)-C(O)-N(R^a)-$, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-;

(d) $-C_0-C_4$-alkyl-C_1-C_4-perfluoroalkyl, or $-O-C_0-C_4$-alkyl-C_1-C_4-perfluoroalkyl; or

(e) CN, NH_2, NO_2, F, Cl, Br, I, OH, $OCON(R^a)(R^b)$ $O(C_1-C_4$-alkyl)$CONR^aR^b$, $-OSO_2N(R^a)(R^b)$, $COOR^b$, $CON(R^a)(R^b)$, or aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) $-NO_2$, iv) $-C(=O)(R^a)$, v) $-OR^a$, vi) $-NR^aR^b$, vii) $-C_{0-4}$alkyl-CO-OR^a, viii) $-(C_{0-4}$alkyl)-NH-CO-OR^a, ix) $-(C_{0-4}$alkyl)-CO-$N(R^a)(R^b)$, x) $-S(O)_{0-2}R^a$, xi) $-SO_2N(R^a)(R^b)$, xii) $-NR^aSO_2R^a$, xiii) $-C_{1-10}$alkyl, and xiv) $-C_{1-10}$alkyl,wherein one or more of the alkyl carbons can be replaced by a $-NR^a-$, -O-, $-S(O)_{1-2}-$, -O-C(O)-, -C(O)-O-, $-C(O)-N(R^a)-$, $-N(R^a)-C(O)-$, $-N(R^a)-C(O)-N(R^a)-$, -C(O)-, -CH(OH)-, -C=C-, or -C≡C; and

R^6, R^7 and R^8 each independently is:

(a) H;

(b) C_1-C_6-alkyl, C_2-C_4-alkenyl, C_3-C_4-alkynyl or C_3-C_6-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF_3, OH, $O-(C_1-C_4)$alkyl, $OCON(R^a)(R^b)$, NR^aR^b,

$COOR^a$, CN, $CONR^aR^b$, $N(R^a)CONR^aR^b$, $N(R^a)SO_2NR^aR^b$, $SO_2NR^aR^b$, $S(O)_{0-2}(C_1-C_4\text{-alkyl})$, $-C(=NH)NH_2$, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl, or piperazinyl;

(c) $-O-C_1-C_6$-alkyl, $-O-C_3-C_6$-cycloalkyl, $-S-C_1-C_6$-alkyl or $-S-C_3-C_6$-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF_3, OH, $O-(C_1-C_4)$alkyl, NH_2, $NH(C_1-C_4\text{-alkyl})$, $N(C_1-C_4\text{-alkyl})_2$, COOH, CN, $CONH_2$, $CONH(C_1-C_4\text{-alkyl})$, $CONH(C_1-C_4\text{-alkyl})_2$, SO_2NH_2, $SO_2NH(C_1-C_4\text{-alkyl})$, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl, or piperazinyl;

(d) $-C_0-C_4$-alkyl-C_1-C_4-perfluoroalkyl, or $-O-C_0-C_4$-alkyl-C_1-C_4-perfluoroalkyl;

(e) -O-aryl, or $-O-C_1-C_4$-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) $-NO_2$, iv) $-C(=O)(R^a)$, v) $-OR^a$, vi) $-NR^aR^b$, vii) $-C_{0-4}$alkyl-CO-OR^a, viii) $-(C_{0-4}\text{alkyl})\text{-NH-CO-}OR^a$, ix) $-(C_{0-4}\text{alkyl})\text{-CO-}N(R^a)(R^b)$, x) $-S(O)_{0-2}R^a$, xi) $-SO_2N(R^a)(R^b)$, xii) $-NR^aSO_2R^a$, xiii) $-C_{1-10}$alkyl, and xiv) $-C_{1-10}$alkyl,wherein one or more of the alkyl carbons can be replaced by a $-NR^a-$, -O-, $-S(O)_{1-2}-$, -O-C(O)-, -C(O)-O-, $-C(O)-N(R^a)-$, $-N(R^a)-C(O)-$, $-N(R^a)-C(O)-N(R^a)-$, -C(O)-, -CH(OH)-, -C=C-, or -C≡C; (f) CN, $N(R^a)(R^b)$, NO_2, F, Cl, Br, I, $-OR^a$, $-SR^a$, $-OCON(R^a)(R^b)$, $-OSO_2N(R^a)(R^b)$, $COOR^b$, $CON(R^a)(R^b)$, $-N(R^a)CON(R^a)(R^b)$, $-N(R^a)SO_2N(R^a)(R^b)$, $-C(OR^b)R^a$, $-C(OR^a)CF_3$, $-C(NHR^a)CF_3$, $-C(=O)R^a$, $C(=O)CF_3$, $-SOCH_3$, $-SO_2CH_3$, $-NHSO_2(C_{1-6}\text{-alkyl})$, $-NHSO_2$-aryl, $SO_2N(R^a)(R^b)$, $-CH_2OSO_2N(R^a)(R^b)$, $SO_2N(R^b)-OR^a$, $-C(=NH)NH_2$, $-CR_a=N-OR_a$, CH=CH or aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) $-NO_2$, iv) $-C(=O)(R^a)$, v) $-OR^a$, vi) $-NR^aR^b$, vii) $-C_{0-4}$alkyl-CO-OR^a, viii) $-(C_{0-4}\text{alkyl})\text{-NH-CO-}OR^a$, ix) $-(C_{0-4}\text{alkyl})\text{-CO-}N(R^a)(R^b)$, x) $-S(O)_{0-2}R^a$, xi) $-SO_2N(R^a)(R^b)$, xii) $-NR^aSO_2R^a$, xiii) $-C_{1-10}$alkyl, and xiv) $-C_{1-10}$alkyl,wherein one or more of the alkyl carbons can be replaced by a $-NR^a-$, -O-, $-S(O)_{1-2}-$, -O-C(O)-, -C(O)-O-, $-C(O)-N(R^a)-$, $-N(R^a)-C(O)-$, $-N(R^a)-C(O)-N(R^a)-$, -C(O)-, -CH(OH)-, -C=C-, or -C≡C; or when R^6 and R^7 are present on adjacent carbon atoms, R^6 and R^7, together with the benzene ring to which they are attached, may form a bicyclic aromatic ring selected from naphthyl, indolyl, quinolinyl, isoquinolinyl, quinoxalinyl. benzofuryl, benzothienyl, benzoxazolyl, benzothiazolyl, and benzimidazolyl, any aromatic ring of which is optionally substituted with 1-4 independent substituents selected from i) halogen, ii) -CN, iii) $-NO_2$, iv) –CHO, v) $-O-C_{1-4}$alkyl, vi) $-N(C_{0-4}\text{alkyl})(C_{0-4}\text{alkyl})$, vii) $-C_{0-4}\text{alkyl-CO-O}(C_{0-4}\text{alkyl})$, viii) $-(C_{0-4}\text{alkyl})\text{-NH-CO-O}(C_{0-4}\text{alkyl})$, ix)

-(C_{0-4}alkyl)-CO-N(C_{0-4}alkyl)(C_{0-4}alkyl), x) -S(C_{0-4}alkyl), xi) -S(O)(C_{1-4}alkyl), xii) -SO_2(C_{0-4}alkyl), xiii) -SO_2N(C_{0-4}alkyl)(C_{0-4}alkyl), xiv) -NHSO_2(C_{0-4}alkyl)(C_{0-4}alkyl), xv) -C_{1-10}alkyl and xvi) -C_{1-10}alkyl in which one or more of the carbons can be replaced by a -N(C_{0-6}alkyl)-, -O-, -$S(O)_{1-2}$-, -O-C(O)-, -C(O)-O-, -C(O)-N(C_{0-6}alkyl)-, -N(C_{0-6}alkyl)-C(O)-, -N(C_{0-6}alkyl)-C(O)-N(C_{0-6}alkyl)-, -C(O)-, -CH(OH), -C=C-, or -C≡C-.

2. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

HET is



3. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

HET is



4. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

HET is



5. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

HET is



6. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

HET is



7. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

HET is



8. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

R^6 is other than H and is attached at the ortho position.

9. A compound represented by



10. A compound according to Claim 1 represented by



R^6	R^2	R^1
Cl	H	H
Cl	H	COOEt
Cl	H	$CONH_2$
Cl	H	CONH-tBu
Cl	H	
Cl	H	NH_2
CF_3	H	COOEt
CF_3	H	$CONH_2$
CF_3	H	H
CF_3	H	NH_2
OCF_3	H	CH_3
OCF_3	H	H
OCF_3	H	NH_2
OCF_3	H	$CONMe_2$

R^6	R^2	R^1
OCF_3	Cl	CH_3
OCF_3	H	$NHSO_2CH_3$
OCF_3	H	CH_2OH
O-Ph	H	$CONH_2$
CF_3	H	NHCONH-iPr
OCF_3	H	NHCONH-iPr
OCF_3	H	$NHCOCH_3$
CF_3	H	$NHCOCH_3$
OCF_3	H	CH_2COOEt
OCF_3	H	CH_2CN
OCF_3	H	CH_2CONH_2
CF_3	H	CH_2CONH_2
OCF_3	H	$NHCONMe_2$
OCF_3	H	
OCF_3	H	2-Pyrimidyl
OCF_3	H	2-Pyridyl
OCF_3	H	2-Oxazolyl
OCF_3	H	2-Imidazolyl
OCF_3	H	2-Pyrazolyl
OCF_3	H	2-(1-Methyl)-imidazolyl
OCF_3	H	
OCF_3	H	
OCF_3	H	

11. A compound represented by



12. A compound according to Claim 1 represented by



R_6	R_2	R_1
CF_3	H	H
CF_3	H	COOEt
CF_3	H	$CONH_2$
CF_3	H	$CONHCH_3$
CF_3	COOEt	CH_3
CF_3	$CONH_2$	CH_3
OCF_3	H	H
OCF_3	H	$COOCH_3$
OCF_3	H	$CONH_2$
OCF_3	H	COOH
OCF_3	H	CH_2OH
OCF_3	H	$CONH(CH_2)_3OH$
O-Ph	H	$CONH_2$

13. A compound represented by



14. A compound according to Claim 1 represented by



R^6	R^3	R^2	R^1
Cl	H	H	H
Cl	H	H	$COOCH_3$
Cl	H	H	$CONH_2$
CF_3	H	H	H
CF_3	H	H	COOH
CF_3	CH_3	H	$CONH_2$
CF_3	H	Cl	$COOCH_3$
CF_3	H	Cl	$CONH_2$
CF_3	H	Cl	Cl
OCF_3	H	H	H
OCF_3	H	H	$COOCH_3$
OCF_3	H	H	$CONH_2$
OCF_3	H	H	

15. A compound represented by



16. A compound according to Claim 1 represented by



R^6	R^2	R^1
Cl	H	CH_3
Cl	H	NH_2
CF_3	H	CH_3
OCF_3	H	NH_2
OCF_3	H	$CH{=}CH_2$
OCF_3	H	$COOCH_3$
OCF_3	H	$CONH_2$
OCF_3	H	CH_3
CF_3	H	NH_2
CF_3	H	H
OCF_3	H	H
Cl	H	COOH
CF_3	H	$CONH_2$
OCF_3	H	$COOCH_2CH_3$

17. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

18. The pharmaceutical composition according to Claim 17, further comprising a second therapeutic agent selected from the group consisting of: i) opiate agonists, ii) opiate antagonists, iii) calcium channel antagonists, iv) 5HT receptor agonists, v) 5HT receptor antagonists vi) sodium channel antagonists, vii) NMDA receptor agonists, viii) NMDA receptor antagonists, ix) COX-2 selective inhibitors, x) NK1 antagonists, xi) non-steroidal anti-inflammatory drugs, xii) selective serotonin reuptake inhibitors, xiii) selective serotonin and norepinephrine reuptake inhibitors, xiv) tricyclic antidepressant drugs, xv) norepinephrine modulators, xvi) lithium, xvii) valproate xviii) neurontin, and xix) antiviral agents.

19. A method of treatment or prevention of pain comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

20. A method of treatment of chronic, visceral, inflammatory and neuropathic pain syndromes comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

21. A method of treatment of pain resulting from, or associated with, traumatic nerve injury, nerve compression or entrapment, postherpetic neuralgia, trigeminal neuralgia, diabetic neuropathy, cancer and chemotherapy, comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

22. A method of treatment of chronic lower back pain comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

23. A method of treatment of phantom limb pain comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

24. A method of treatment of HIV- and HIV treatment-induced neuropathy, chronic pelvic pain, neuroma pain, complex regional pain syndrome, chronic arthritic pain and related neuralgias

comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

25. A method of administering local anesthesia comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

26. A method of treatment of irritable bowel syndrome and Crohn's disease comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

27. A method of treatment of epilepsy and partial and generalized tonic seizures comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

28. A method for neuroprotection under ischaemic conditions caused by stroke or neural trauma comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of thecompound according to Claim 1, or a pharmaceutically acceptable salt thereof.

29. A method of treatment of multiple sclerosis comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

30. A method of treatment of bipolar disorder comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

31. A method of treatment of tachy-arrhythmias comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.